Too many families know first-hand how progressive neurological diseases can rob people of their personality and turn loved ones into strangers. These diseases are not only severe; they’re also deadly. The World Health Organization estimates that neurological disorders cause 12 percent of the world’s deaths.

Central nervous system (CNS) disorders include devastating diseases and conditions that have afflicted generations and affect more than one billion people worldwide. The names of these diseases are familiar—brain tumors, epilepsy, Parkinson’s disease, multiple sclerosis, Huntington’s disease, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and rare genetic disorders such as lysosomal storage diseases including Hunter and Hurler syndromes, among others. In too many cases potential treatments have failed in these disease areas because most drugs are not developed to deliver sufficient payloads to the brain.

Today, scientists are beginning to understand the extraordinary complexity of CNS and how to investigate further into its mysteries. The biopharmaceutical industry has advanced the field of neuroscience where delivery of therapies into the brain is possible. The key to our approach is the xB3 platform, specifically designed to deliver greater quantities of drug across the blood-brain barrier and into the brain.

Deborah Rathjen Speaks to Proactive

Mei Mei Tian Speaks to Stockhouse

Deborah Rathjen on the Big Biz Radio Show